Searchable abstracts of presentations at key conferences in endocrinology

ea0022p396 | Endocrine tumours &amp; neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

Outcome of two chemotherapies in the treatment of progressive, undifferentiated neuroendocrine carcinomas: a single-center experience

Deutschbein Timo , Unger Nicole , Yuece Ali , Lahner Harald , Mann Klaus , Petersenn Stephan

Introduction: Treatment of poorly differentiated neuroendocrine tumors (NET) usually includes chemotherapeutic intervention. However, both the rarity and the heterogeneity of the disease have led to relatively few clinical trials. This study evaluated the outcome of two chemotherapy regimens in patients suffering from undifferentiated and histologically confirmed NET.Methods: Eighteen patients (11 males; age 56.7±2.5) with proven progressive disease...

ea0016p476 | Neuroendocrinology | ECE2008

Prospective comparison of the glucagon stimulation test (GST) with the insulin tolerance test (ITT) in patients following pituitary surgery

Berg Christian , Meinel Timo , Yuece Ali , Lahner Harald , Mann Klaus , Petersenn Stephan

Objective: The ITT is the gold-standard for assessment of GH and ACTH reserve but has certain contraindications. GH and cortisol responses of <3 ng/ml and <500 nmol/l, respectively, have been defined as evidence of severe deficiency. The GST like the ITT stimulates both the ACTH and GH secretion and is suggested to be a good alternative in terms of efficiacy. However, there are limited prospective data with modern assays on sensitivity and specificity for the GST in co...

ea0049gp177 | Pituitary | ECE2017

Octreotide subcutaneous (s.c.) depot, a novel ready-to-use formulation, provides higher exposure and maintains response in patients with acromegaly and functioning neuroendocrine tumours (NETs) previously treated with long-acting octreotide: Results from a phase 2, open-label, multicentre, randomized study

Ferone Diego , Borson-Chazot Francoise , Cailleux Anne , Horsch Dieter , lahner Harald , Pivonello Rosario , Tauchmanova Libuse , Darstein Christelle , Olsson Hakan , Tiberg Fredrik , Pavel Marianne

Background: Octreotide s.c. depot is a novel, ready-to-use formulation administered via a thin needle, which may allow self-administration. In a phase 1 study in healthy volunteers, octreotide s.c. depot provided greater bioavailability with faster onset and greater IGF1 suppression than long-acting octreotide. Here, we present data from a phase 2 study evaluating pharmacokinetics (PK), efficacy, safety, and tolerability of octreotide s.c. depot in patients with acromegaly and...

ea0016p738 | Thyroid | ECE2008

Iodine excretion and prevalence of thyroid dysfunction in the Western Part of Germany: results of the Heinz Nixdorf Recall study

Broecker-Preuss Martina , Lahner Harald , Moebus Susanne , Moehlenkamp Stefan , Roggenbuck Ulla , Joeckel Karl-Heinz , Erbel Raimund , Mann Klaus , on behalf of the Heinz Nixdorf Recall Investigator Group

Objective: While Germany was considered to be an iodine deficient area grade I to II in 1993, iodine supply has increased. With higher iodine uptake, prevalence of autoimmune thyroiditis may increase. Poor data exist on iodine supply and the occurrence of thyroid dysfunction in middle-aged adults in the western part of Germany. The aim of our study was to analyze iodine status, prevalence of TPO-antibodies (TPOab), TSH and fT4 levels in a large population-based sample in the w...